Infective Endocarditis

Table of Contents

1. Overview
2. Epidemiology
3. Microbiology and Pathogens
4. Risk Factors
5. Diagnosis and Duke Criteria
6. Echocardiography and Imaging
7. Complications
8. Treatment
9. Surgical Indications
10. Prevention and Prophylaxis
11. Prognosis
12. Research Papers
13. Connections
14. Featured Videos

Back to Table of Contents

1. Overview

Infective endocarditis (IE) is an infection of the cardiac endothelium — the inner lining of the heart — most commonly involving the native or prosthetic cardiac valves, although it can also affect intracardiac devices such as pacemaker leads and implantable cardioverter-defibrillators. Despite advances in diagnosis and treatment, IE remains a life-threatening condition with in-hospital mortality rates of 15–20% and substantial long-term morbidity from valvular destruction, embolic stroke, and heart failure.

Clinicians traditionally divide IE into two main clinical syndromes based on pace and severity:

• Acute IE — caused predominantly by Staphylococcus aureus, this form is fulminant, progresses over days to weeks, rapidly destroys valvular tissue, and carries in-hospital mortality of 25–45%. It can infect previously normal valves.
• Subacute IE — caused predominantly by viridans group streptococci and Enterococcus species, this form progresses insidiously over weeks to months, typically on pre-existing abnormal valves. Constitutional symptoms dominate, and it is more frequently associated with the classic immunologic phenomena (Osler nodes, Roth spots, glomerulonephritis).

In the United States, the incidence of IE is approximately 15 cases per 100,000 person-years, and this figure has been rising over recent decades. The increase is driven by three converging trends: the escalating opioid epidemic with intravenous drug use (IVDU), a growing population of patients with prosthetic heart valves, and the expanding use of intracardiac electronic devices (pacemakers, defibrillators, and cardiac resynchronization therapy devices). These exposures create portals for bacteremia that bypass the normal skin and mucosal barriers.

Pathophysiology

The sequence of events leading to IE involves several steps that must occur in succession:

1. Endothelial disruption or turbulence. Normally, the smooth endocardium is resistant to bacterial colonization. High-velocity jets of blood (as in mitral regurgitation, bicuspid aortic valve, or ventricular septal defect) cause mechanical injury, exposing the underlying collagen matrix. Prosthetic materials also provide a scaffold for platelet adherence.
2. Non-bacterial thrombotic endocarditis (NBTE). Exposed subendothelial collagen and tissue factor trigger the coagulation cascade, depositing a sterile platelet-fibrin thrombus — the nidus for subsequent bacterial colonization. NBTE is also seen in hypercoagulable states and marantic endocarditis (malignancy, chronic illness).
3. Bacteremia. Transient bacteremia from dental procedures, skin and soft-tissue infections, gastrointestinal manipulation, or urogenital instrumentation seeds the bloodstream. In IVDU, direct inoculation of organisms into the venous circulation provides a sustained, high-grade bacteremia with organisms that would not normally reach the heart.
4. Bacterial colonization and vegetation formation. Bacteria with adhesins (surface proteins that bind fibronectin, laminin, and fibrinogen) attach to the NBTE thrombus. S. aureus and viridans streptococci are particularly adept at this. Once attached, bacteria proliferate within the protective fibrin-platelet matrix — shielded from complement, opsonins, and phagocytes — forming the characteristic vegetation: a friable mass of bacteria, fibrin, platelets, and inflammatory cells on the valve leaflet. Vegetations are typically located on the low-pressure side of the valve (atrial surface of AV valves; ventricular surface of semilunar valves), corresponding to where the high-velocity jet impacts.
5. Tissue destruction and systemic seeding. Proteases and toxins from the bacteria (especially S. aureus) destroy valvular leaflets and chordae tendineae, leading to acute regurgitation. Fragments of the vegetation embolize to the coronary, cerebral, splenic, renal, and peripheral circulation, causing septic infarcts and metastatic infections.

Understanding this pathophysiology explains why IE therapy requires prolonged high-dose bactericidal agents: antibiotics must penetrate the dense fibrin matrix to reach organisms growing at concentrations far exceeding the minimum bactericidal concentration (MBC).

Back to Table of Contents

2. Epidemiology

The epidemiology of infective endocarditis has shifted markedly over the past 50 years. The condition once predominantly affected young patients with rheumatic heart disease or congenital heart defects. Today it is more frequently a disease of older adults with degenerative valve disease, prosthetic valve recipients, and younger individuals caught in the opioid epidemic.

Incidence and Demographics

The annual incidence in high-income countries is 3–15 cases per 100,000 person-years, with the US consistently at the higher end (~15/100,000). Incidence increases sharply with age, reaching over 30/100,000 in adults over 70. Men are affected approximately twice as often as women (2:1 male-to-female ratio), reflecting higher rates of IVDU and greater burden of aortic valve disease in men.

Intravenous Drug Use (IVDU)-Associated IE

IVDU represents the single highest relative-risk exposure for IE. Repeated injection with non-sterile equipment introduces high-density bacteremia directly into the venous circulation, most commonly with S. aureus (skin flora on the injecting arm). Unlike non-IVDU IE, IVDU-associated IE predominantly involves the tricuspid valve (right-sided) because venous blood returns first to the right heart before passing through the pulmonary circulation. Right-sided IE, though caused by virulent S. aureus, carries a paradoxically favorable prognosis (5–10% in-hospital mortality) compared to left-sided IE, because pulmonary emboli — while causing septic pulmonary infarcts — are generally less immediately life-threatening than systemic emboli to the brain or coronary arteries. However, recidivism is high in patients who return to active drug use, and each recurrence carries its own mortality risk.

Prosthetic Valve Endocarditis (PVE)

PVE accounts for approximately 20–30% of all IE cases in developed countries. It is classified by timing relative to valve implantation:

• Early PVE (within 60 days of surgery): nosocomial origin — contamination at the time of surgery or from a postoperative source. Causative organisms include S. aureus, coagulase-negative staphylococci (CoNS, predominantly S. epidermidis), gram-negative bacilli (Pseudomonas, Enterobacter), and fungi (Candida). Biofilm formation on the prosthetic ring makes these infections extremely difficult to eradicate with antibiotics alone.
• Late PVE (beyond 60 days, especially >1 year): microbiology resembles native valve endocarditis, with viridans streptococci, S. aureus, and enterococci predominating. Late PVE arises from transient community-acquired bacteremia seeding a prosthetic substrate.

Mechanical and bioprosthetic valves carry similar overall IE risk during the first year. After 5–7 years, bioprosthetic valves have a higher risk as leaflet degeneration creates nidus for bacterial colonization.

Healthcare-Associated IE

Healthcare-associated IE now accounts for 25–30% of all cases. Risk factors include: central venous catheters, hemodialysis access (arteriovenous fistulas and tunneled catheters), peripheral IV catheters, urinary catheters, and surgical wounds. Hemodialysis patients face particularly high IE risk — their annual incidence exceeds 300/100,000, more than 20-fold the background rate. S. aureus (particularly MRSA) predominates.

Cardiac Implantable Electronic Device (CIED) IE

CIED infections — affecting pacemakers, ICDs, and CRT devices — are a distinct and growing subset. The infection originates at the device pocket (wound infection) or along the transvenous lead, and can extend to the tricuspid valve or superior vena cava. Diagnosis and management differ from native valve IE: complete device extraction (leads included) is typically required for cure, and lead extraction carries its own procedural risk.

Back to Table of Contents

3. Microbiology and Pathogens

The microbiology of IE reflects which organisms most effectively combine the ability to cause sustained bacteremia with surface adhesins that permit cardiac endothelial colonization. Approximately 90% of culture-positive cases are caused by staphylococci, streptococci, or enterococci.

Staphylococcus aureus

S. aureus is now the single most common cause of IE in most developed-world registries, responsible for 25–35% of cases. It is the dominant organism in IVDU-associated IE, nosocomial/healthcare-associated IE, and intravascular device-related IE. S. aureus is uniquely dangerous for several reasons:

• It possesses a rich arsenal of adhesins — fibronectin-binding proteins A and B (FnBP-A/B), clumping factors A and B (ClfA/B), and iron-regulated surface determinants — that mediate high-affinity binding to cardiac tissue even without prior endothelial damage.
• It produces toxins (alpha-toxin, Panton-Valentine leukocidin in some strains) and proteases that rapidly destroy valvular architecture.
• It forms biofilms on prosthetic material, making eradication extremely difficult.
• Methicillin-resistant S. aureus (MRSA) is present in 20–40% of community-associated and over 50% of healthcare-associated cases, narrowing antibiotic options.

S. aureus IE carries in-hospital mortality of 25–45%. Persistent bacteremia beyond 72 hours of appropriate antibiotics is common and strongly predicts embolic events, metastatic infection, and death.

Viridans Group Streptococci

Viridans streptococci (S. viridans, S. sanguinis, S. mutans, S. mitis, and related species) are commensal oral flora that enter the bloodstream during dental procedures and even routine activities like tooth brushing and chewing. They are the classic cause of subacute native valve endocarditis, accounting for 15–25% of cases. They typically infect pre-existing abnormal valves (rheumatic, bicuspid, or myxomatous mitral) and progress slowly. The majority are exquisitely sensitive to penicillin (MIC ≤0.12 mg/L), making treatment straightforward. Mortality with appropriate therapy is under 5%.

Streptococcus gallolyticus (formerly S. bovis)

S. gallolyticus (reclassified from Streptococcus bovis) is associated with colorectal cancer and adenomatous polyps. Its isolation from blood cultures in the context of IE is a strong indication for colonoscopy, even in the absence of gastrointestinal symptoms — studies report that 25–80% of patients with S. bovis/gallolyticus IE have underlying colorectal neoplasia. The organism behaves microbiologically like viridans streptococci (typically penicillin-sensitive) but mandates a colon cancer workup.

Enterococcus

Enterococcus faecalis (predominant, ~90%) and E. faecium cause 5–15% of IE, arising from gastrointestinal or genitourinary sources (colonoscopy, cystoscopy, urinary tract infection, prostate procedures). Enterococci are intrinsically resistant to many antibiotics and require combination therapy for killing. The traditional regimen is ampicillin plus gentamicin (synergistic bactericidal effect through cell wall inhibition plus aminoglycoside ribosomal penetration); however, high-level aminoglycoside resistance (HLAR) in some strains renders gentamicin ineffective, and the ACEI (Ampicillin-Ceftriaxone-Endocarditis-IE) trial validated ampicillin plus ceftriaxone as an equally effective and nephrotoxicity-sparing alternative for E. faecalis IE.

Coagulase-Negative Staphylococci (CoNS)

CoNS — predominantly Staphylococcus epidermidis — are the leading cause of early prosthetic valve endocarditis, responsible for 15–40% of PVE cases. They are biofilm formers par excellence, colonizing prosthetic surfaces within hours of implantation. The vast majority of PVE CoNS are oxacillin-resistant (equivalent of MRSA for CoNS), requiring vancomycin-based regimens typically combined with rifampin and gentamicin to penetrate biofilm.

HACEK Organisms

The HACEK group — Haemophilus spp. (especially H. parainfluenzae), Aggregatibacter spp. (formerly Actinobacillus and Haemophilus aphrophilus), Cardiobacterium hominis, Eikenella corrodens, and Kingella kingae — are fastidious gram-negative organisms found in the normal oral flora. They account for 1–3% of IE cases, characteristically presenting as subacute endocarditis with large friable vegetations and high embolic risk. They require specialized blood culture conditions (extended incubation) or 16S rRNA PCR for identification. Treatment is ceftriaxone 2g/day for 4 weeks.

Culture-Negative IE

Blood cultures remain sterile in 5–10% of IE cases. The most common explanations are prior antibiotic administration, fastidious organisms that do not grow in standard culture media, and intracellular pathogens. Key entities include:

• Coxiella burnetii (Q fever): Acquired from contact with infected farm animals (cattle, sheep, goats), parturient cats. Diagnosis by serology (phase I anti-IgG titer >1:800 is a major Duke criterion). Treatment requires prolonged doxycycline plus hydroxychloroquine (to increase phagolysosomal pH, enhancing doxycycline activity) for a minimum of 18 months.
• Bartonella species: B. quintana (homeless individuals, body lice) and B. henselae (cat-scratch disease, kitten exposure). Diagnosis by serology and blood or tissue PCR. Treatment: ceftriaxone plus doxycycline for 6 weeks.
• Tropheryma whipplei: Causative agent of Whipple's disease; rare but important cause of culture-negative IE, sometimes presenting without the gastrointestinal manifestations. Diagnosis by PCR on valve tissue or blood.
• Prior antibiotic therapy: The most common cause of initially culture-negative IE. Blood cultures should be repeated after a 48–72 hour antibiotic-free window if clinical stability allows.

Fungal IE

Fungal IE is uncommon but devastating, with mortality exceeding 50% with medical therapy alone. Candida species predominate, followed by Aspergillus. Risk groups include: prolonged IV line use (total parenteral nutrition, chemotherapy), IVDU, immunosuppression (solid-organ transplant, hematologic malignancy), and prolonged broad-spectrum antibiotic use. Fungal vegetations are typically very large (>10mm), with extremely high embolic risk. Management requires surgical valve replacement plus prolonged antifungal therapy (typically liposomal amphotericin B acutely, followed by long-term azole suppression). Cure without surgery is exceedingly rare.

Back to Table of Contents

4. Risk Factors

Risk for IE is determined by the probability of bacteremia (exposure risk) multiplied by the susceptibility of the cardiac substrate to endothelial colonization.

Cardiac Risk Factors

• Prior IE: The single strongest predictor of recurrent IE. Scar tissue, valve irregularity, and disrupted endothelium from prior infection create persistent high-risk substrate.
• Prosthetic heart valves: The prosthetic ring and sutured tissue are non-endothelialized surfaces that remain susceptible to colonization indefinitely. Both mechanical and bioprosthetic valves carry elevated risk.
• Congenital heart disease (CHD): Cyanotic unrepaired CHD (especially tetralogy of Fallot, single-ventricle lesions) and repaired CHD with residual defects or prosthetic material used within the past 6 months carry the highest risk. Isolated atrial septal defects (secundum type) are not high-risk. The AHA classifies repaired CHD with prosthetic patches or conduits, if residual shunt or regurgitation remains adjacent to the prosthetic material, as high-risk.
• Rheumatic heart disease: Mitral stenosis and aortic regurgitation from rheumatic fever damage the valve surface and create turbulent flow — the combination that predisposes to IE. Globally, rheumatic heart disease remains the dominant predisposing condition in low- and middle-income countries.
• Mitral valve prolapse (MVP) with mitral regurgitation (MR): MVP without MR carries minimal excess risk. The presence of a murmur from regurgitation elevates risk modestly.
• Bicuspid aortic valve: Present in 1–2% of the population; the abnormal valve architecture creates turbulent flow and endothelial damage, substantially elevating IE risk.
• Hypertrophic obstructive cardiomyopathy (HOCM): The dynamic outflow tract obstruction and associated MR create the hemodynamic conditions for endothelial injury, particularly at the contact point of the anterior mitral leaflet with the septal endocardium.
• Cardiac implantable electronic devices (CIEDs): Pacemaker and ICD leads provide a prosthetic surface from the device pocket through the venous circulation to the tricuspid valve. The pocket wound is the most common infection entry point.

Non-Cardiac Risk Factors

• Intravenous drug use (IVDU): The highest relative-risk non-cardiac exposure. Recurrent, high-density bacteremia with skin flora (S. aureus) directly into the venous circulation overwhelms normal host defenses. The risk is amplified by injection of particulate matter (talc, cotton) that damages tricuspid valve endothelium directly.
• Intravascular catheters: Central venous catheters (CVC), peripherally inserted central catheters (PICCs), hemodialysis tunneled catheters, and arteriovenous fistulas are portals for bacteria. The risk of catheter-associated bloodstream infection increases with catheter dwell time and number of manipulations.
• Hemodialysis: Among the highest-risk populations; bacteremia rates are approximately 1 per 100 patient-months, driven by dialysis access infection. Annual IE incidence in hemodialysis patients exceeds 1%.
• Poor dentition and periodontal disease: Provides a continuous low-grade source of oral flora bacteremia. Maintaining dental hygiene is one of the most actionable risk-reduction strategies.
• Immunosuppression: HIV (particularly with low CD4 counts), solid-organ transplant recipients, hematologic malignancy, and prolonged corticosteroid use all increase susceptibility to bacteremia and fungal infection.
• Diabetes mellitus: Impairs neutrophil function and mucosal barrier integrity; associated with a 2–3-fold increased IE risk independent of other factors.
• Malignancy: Marantic (non-bacterial thrombotic) endocarditis in patients with advanced cancer provides an NBTE nidus; also, indwelling catheters for chemotherapy and immunosuppression compound the risk.

Back to Table of Contents

5. Diagnosis and Modified Duke Criteria

The Modified Duke Criteria, originally proposed by Durack et al. in 1994 and revised by Li et al. in 2000, provide a standardized diagnostic framework that integrates clinical, microbiological, and echocardiographic findings. The criteria classify IE as Definite, Possible, or Rejected.

Blood Cultures — The Cornerstone of Diagnosis

Blood cultures must be obtained before initiating antibiotics. The recommended approach is:

• Draw at least 3 sets (one aerobic + one anaerobic bottle per set = 6 bottles total) from 3 separate venipuncture sites.
• Separate draws by at least 15–30 minutes (or simultaneously if the patient is critically ill and antibiotics cannot be safely delayed).
• Each bottle should contain 8–10 mL of blood — volume is the single most important determinant of culture yield.
• Notify the laboratory of suspected IE so bottles are held for extended incubation (14–21 days) to allow recovery of fastidious organisms (HACEK, Brucella).
• If cultures remain negative at 5–7 days and IE is still suspected, send specific serology for Coxiella, Bartonella, and Brucella, and consider 16S rRNA PCR on blood or request excised valve tissue.

Major Duke Criteria

1. Positive blood cultures:
   • Two separate positive blood culture sets with a typical IE organism: S. aureus, viridans group streptococci, S. gallolyticus, HACEK group, or community-acquired Enterococcus faecalis (without a primary focus); OR
   • Persistently positive blood cultures: ≥2 positive cultures drawn >12 hours apart, OR 3 of 3 or ≥3 of 4 positive cultures (with first and last drawn at least 1 hour apart); OR
   • Single positive blood culture for Coxiella burnetii, or phase I anti-IgG antibody titer >1:800.
2. Evidence of endocardial involvement (echocardiographic or new regurgitation):
   • Oscillating intracardiac mass on a valve or supporting structure, in the path of regurgitant jets, or on implanted prosthetic material, in the absence of an alternative anatomical explanation (vegetation); OR
   • Perivalvular abscess (ring abscess); OR
   • New partial dehiscence of a prosthetic valve; OR
   • New valvular regurgitation (worsening or change in a pre-existing murmur is insufficient).

Minor Duke Criteria

1. Predisposing condition: cardiac (as above) or IVDU.
2. Fever: temperature >38.0°C (100.4°F).
3. Vascular phenomena: arterial emboli, septic pulmonary infarcts (in right-sided IE), mycotic aneurysm, intracranial hemorrhage (from rupture of mycotic aneurysm), conjunctival hemorrhages, Janeway lesions.
4. Immunologic phenomena: glomerulonephritis, Osler nodes, Roth spots, positive rheumatoid factor.
5. Microbiological evidence: positive blood culture not meeting major criteria, or serological evidence of active infection with an organism consistent with IE.

Classification

• Definite IE: 2 major criteria; OR 1 major + 3 minor criteria; OR 5 minor criteria; OR pathological criteria (organisms on culture or histology from a vegetation, embolized vegetation, or intracardiac abscess).
• Possible IE: 1 major + 1 minor criterion; OR 3 minor criteria.
• Rejected: Firm alternative diagnosis; OR resolution of IE-compatible syndrome with ≤4 days of antibiotic therapy; OR no pathological evidence of IE at surgery or autopsy after ≤4 days of antibiotic therapy.

Classic Physical Examination Findings

The peripheral manifestations of IE arise from two mechanisms: immune complex deposition (subacute IE, viridans strep) and septic microemboli (acute IE, S. aureus):

• Roth spots: Oval retinal hemorrhages with pale centers on fundoscopy. Caused by immune complex vasculitis of retinal capillaries. Named for Moritz Roth. Not pathognomonic — also seen in leukemia, hypertensive retinopathy, and anemia.
• Osler nodes: Painful, raised, erythematous nodules on the finger pads and toes. Caused by immune complex deposition with microemboli. Tender to palpation; often transient (hours to days). Named for Sir William Osler, who characterized subacute IE comprehensively in the 1880s.
• Janeway lesions: Non-tender, irregular erythematous macules or hemorrhagic plaques on the palms and soles. Caused by septic microemboli — painless because they are superficial skin infarcts without neural involvement. More common in acute S. aureus IE.
• Splinter hemorrhages: Linear dark streaks under the fingernails and toenails, representing microemboli in the nail bed capillaries. Non-specific (also from trauma), but multiple simultaneous lesions in the context of fever are suggestive.
• New or changing cardiac murmur: A new or changed regurgitant murmur in a febrile patient is a cardinal finding. The Osler dictum "always think of endocarditis" applies whenever a new murmur accompanies unexplained fever.
• Splenomegaly: Present in up to 40% of subacute IE; less common in acute IE. Reflects reticuloendothelial hyperplasia and immunologic activation.

Back to Table of Contents

6. Echocardiography and Imaging

Echocardiography is the principal imaging modality in IE, serving to confirm the diagnosis, characterize vegetations, identify complications (perivalvular abscess, fistula, chordal rupture, valve perforation), and guide surgical planning. The choice between transthoracic (TTE) and transesophageal (TEE) echocardiography depends on clinical context and image quality.

Transthoracic Echocardiography (TTE)

TTE is the appropriate first-line study in suspected IE. It is non-invasive, widely available, and provides good visualization of the left ventricular function and mitral and aortic valves in most patients. Sensitivity for vegetation detection ranges from 40–80% — highly variable depending on image quality (body habitus, lung disease), vegetation size, and echocardiographer experience. Specificity is higher (~90%). Small vegetations (<5mm), prosthetic valve shadowing, and posterior structures (tricuspid valve, pulmonary valve, intracardiac leads) are limitations of TTE.

Transesophageal Echocardiography (TEE)

TEE is mandatory and should be performed early in the following settings:

• Prosthetic valve IE (acoustic shadowing on TTE limits sensitivity to <50% for prosthetic valves)
• S. aureus bacteremia (high IE pretest probability regardless of initial TTE)
• Intracardiac device IE (pacemaker/ICD leads poorly visualized on TTE)
• Suspected perivalvular abscess or fistula
• Inadequate or non-diagnostic TTE in a patient with high clinical suspicion
• Planned valve surgery (detailed anatomical delineation for surgical planning)

TEE sensitivity for vegetations reaches 85–95%, with superior resolution of posterior structures (mitral subvalvular apparatus, aortic valve perivalvular extension, prosthetic valve rings). TEE is semi-invasive (oropharyngeal probe under conscious sedation) with rare but real risks (esophageal perforation in <0.1%, aspiration, arrhythmia).

Vegetation Characteristics and Embolic Risk

Echocardiographic vegetation characteristics predict the risk of systemic embolization — the most feared complication of left-sided IE:

• Size: Vegetations >10mm carry significantly higher embolic risk than smaller lesions. Those >15mm on the mitral valve carry particularly high risk, as they are large enough to fragment and occlude cerebral vessels.
• Mobility: Highly mobile, pedunculated vegetations are more prone to fragmentation and embolization than sessile lesions.
• Location: Anterior mitral leaflet vegetations embolize more frequently than posterior leaflet or aortic valve vegetations, possibly due to motion dynamics.
• Growth under therapy: Vegetation enlargement despite appropriate antibiotics is an indication for surgery, as it portends treatment failure and progressive valve destruction.

Advanced Imaging Modalities

• 18F-FDG PET/CT: Increasingly adopted for prosthetic valve IE, where TEE is limited by metallic acoustic shadowing (especially mechanical valves). FDG accumulation around the prosthetic valve reflects inflammatory/infectious activity. Also valuable for detecting metastatic infectious foci (vertebral osteomyelitis, psoas abscess, septic pulmonary emboli) and secondary portal infections that would alter the duration of antibiotic therapy. The 2023 ESC guidelines incorporated FDG-PET/CT as a major diagnostic criterion for prosthetic valve and CIED endocarditis.
• Cardiac CT: Provides excellent spatial resolution for complex perivalvular anatomy — abscesses, pseudoaneurysms, fistulae, and their relationship to surrounding structures. Particularly useful preoperatively to plan the extent of debridement and reconstruction needed.
• Brain MRI: Clinically silent cerebral emboli occur in 65–80% of left-sided IE patients studied with MRI — far more common than clinical stroke rates suggest. Microemboli appear as scattered DWI-positive cortical lesions. MRI influences surgical timing decisions: hemorrhagic transformation contraindicates surgery for several weeks (4-week delay), while non-hemorrhagic emboli may permit earlier surgery.
• Whole-Body CT: To evaluate for extracardiac complications: splenic infarcts/abscesses, renal infarcts, vertebral osteomyelitis, and mycotic aneurysms of peripheral or visceral arteries.

Back to Table of Contents

7. Complications

IE is a systemic disease whose complications arise from three principal mechanisms: direct local valve destruction, embolization of vegetations, and immune-mediated organ damage. Recognizing and managing these complications often determines survival.

Heart Failure

Heart failure (HF) is the most common complication of IE (occurring in 50–60% of left-sided cases) and the most common indication for emergency surgery. It arises primarily from acute severe valvular regurgitation caused by:

• Valve leaflet perforation or destruction
• Rupture of chordae tendineae supporting the mitral valve
• Partial or complete prosthetic valve dehiscence
• Obstruction of valve orifice by a large vegetation (rare)

The left ventricle accommodates chronic MR through compensatory dilatation; however, acute severe MR (as in IE) overwhelms this mechanism, causing rapid pulmonary edema. Acute severe aortic regurgitation similarly produces acute hemodynamic collapse. Medical management (vasodilators, diuretics) provides only temporary stabilization — definitive treatment is urgent surgical valve repair or replacement.

Systemic Embolization

Embolism from left-sided IE vegetations occurs in 20–50% of patients, most commonly to the brain, spleen, kidneys, and coronary arteries. The risk is highest in the first 2 weeks of treatment, before antibiotic therapy sterilizes and reduces vegetation size. After 2 weeks of effective therapy, new embolic risk drops dramatically. Key embolic manifestations:

• Cerebrovascular events: Stroke (ischemic or hemorrhagic) or TIA occurs in 15–30% of left-sided IE. Ischemic stroke results from vegetation fragments occluding cerebral arteries; hemorrhagic stroke from rupture of mycotic aneurysms. Cerebrovascular events dramatically worsen prognosis, both by causing direct neurological injury and by complicating the timing of cardiac surgery.
• Splenic emboli: Splenic infarcts occur in 20–40% of cases (often clinically silent). Large infarcts can cavitate to form splenic abscesses (usually 2–4 weeks after bacteremia), which require splenectomy or percutaneous drainage and may serve as a reservoir for relapse.
• Renal infarcts: Present in up to 30% on CT; mostly subclinical but can cause flank pain and hematuria.
• Coronary emboli: Septic emboli to the coronary ostia produce ST-elevation myocardial infarction, which may be the presenting manifestation of IE in acute S. aureus cases.
• Septic pulmonary emboli: In right-sided (tricuspid) IE, emboli lodge in the pulmonary vasculature, causing multiple bilateral peripheral nodular infiltrates — a characteristic pattern on chest CT. They may cavitate (septic lung abscesses).

Perivalvular Extension and Abscess

Perivalvular (ring) abscess develops when infection erodes beyond the valve leaflets into the annular tissue and adjacent cardiac structures. It occurs in:

• 30–40% of prosthetic valve IE (sewing ring is a primary site of extension)
• 10–15% of native valve aortic IE (dense fibroelastic annulus allows local extension)

The anatomical proximity of the aortic valve annulus to the AV node and His bundle means that perivalvular abscess frequently causes heart block (first-degree, second-degree, or complete). A new conduction abnormality in a patient with aortic IE is a red flag for abscess formation. Abscess can also extend to create:

• Fistulae: Aorta-to-left-atrium, aorta-to-right-ventricle, or aorta-to-right-atrium fistulae cause new murmurs and hemodynamic compromise.
• Pseudoaneurysms: Blood-filled cavities communicating with a cardiac chamber or great vessel — at high risk of rupture.

Perivalvular abscess is universally an indication for surgery. Medical therapy alone virtually never eradicates it.

Mycotic Aneurysm

Mycotic aneurysms form when septic emboli lodge in the vasa vasorum (small vessels supplying the arterial wall), causing focal wall infection, weakening, and aneurysm formation. They most commonly involve intracranial arteries (especially middle cerebral artery branches) — asymptomatic until rupture causes catastrophic intracranial hemorrhage. In IE patients with unexplained headache or neurological symptoms, intracranial CT angiography or MR angiography should be performed to screen for mycotic aneurysms. Management options include close serial imaging (small, unruptured), endovascular coiling, or surgical clipping (ruptured or enlarging lesions).

Persistent Bacteremia and Metastatic Infection

Bacteremia lasting beyond 72 hours despite appropriate antibiotics suggests either an uncontrolled intracardiac source (perivalvular abscess, large vegetation), a metastatic infectious focus (vertebral osteomyelitis, septic arthritis, psoas abscess, epidural abscess), or an undrained peripheral source (septic thrombophlebitis). Metastatic IE infection requires antibiotic courses tailored to the specific focus (often 6+ weeks for vertebral osteomyelitis) and may require separate surgical or interventional drainage.

Immune-Mediated Complications

Sustained antigenemia in subacute IE drives immune complex formation and deposition:

• Immune complex glomerulonephritis: Occurs in up to 30% of subacute IE. Presents with hematuria, proteinuria, and elevated creatinine. Resolves with successful treatment of IE, without requiring immunosuppressive therapy.
• Rheumatoid factor: Found in 40–50% of subacute IE; clears with treatment.

Back to Table of Contents

8. Treatment — Antibiotics

The pharmacological principles of IE therapy are defined by the biology of the vegetation: bacteria grow within a dense fibrin-platelet matrix at very high densities, in a metabolically heterogeneous microenvironment that renders many bacteria tolerant to cell-wall-active agents. Effective treatment requires:

• Bactericidal agents (not merely bacteriostatic): the fibrin matrix excludes phagocytes, so the antibiotic must kill the organism without host immune assistance.
• High serum concentrations that exceed the minimum bactericidal concentration (MBC), not just the MIC.
• Prolonged therapy (4–6 weeks) to allow antibiotic penetration into the vegetation matrix and sterilization of all organisms.
• Synergistic combinations (in specific settings, e.g., enterococcal IE) that achieve killing that neither drug alone can.

Native Valve Staphylococcal IE

• MSSA (methicillin-susceptible S. aureus): Nafcillin or oxacillin 2g IV every 4 hours for 6 weeks. These semisynthetic penicillinase-resistant beta-lactams remain the agents of choice for MSSA — clinically superior to vancomycin (higher mortality with vancomycin for MSSA IE in multiple observational studies). If the patient has a non-anaphylactic penicillin allergy: cefazolin 2g IV every 8 hours (safe and effective; reserve PCN skin testing or desensitization for true anaphylaxis history).
• MRSA: Vancomycin 15–20 mg/kg IV every 8–12 hours, adjusted for renal function, targeting a trough of 15–20 mg/L or, preferably, an AUC/MIC of 400–600 mg·h/L (per updated ASHP/IDSA/SIDP guidance). Alternative for MRSA IE when vancomycin MIC is >1 mg/L or renal toxicity is a concern: daptomycin 8–10 mg/kg/day IV. Critical caveat: daptomycin is inactivated by pulmonary surfactant and must NOT be used for MSSA or MRSA IE with pulmonary involvement (right-sided IE with septic pulmonary emboli).

Prosthetic Valve Staphylococcal IE

Combination therapy is required for prosthetic valve IE due to biofilm formation. The standard regimen for MSSA PVE is nafcillin + rifampin 300mg PO every 8 hours + gentamicin 1mg/kg IV every 8 hours. Rifampin is uniquely able to penetrate staphylococcal biofilm and achieve bactericidal activity against sessile organisms, but must never be used as monotherapy (rapid resistance emergence). Gentamicin is added during the first 2 weeks for initial bactericidal synergy. For MRSA PVE: vancomycin (or daptomycin) + rifampin + gentamicin × 6 weeks minimum.

Streptococcal IE

• Highly penicillin-susceptible viridans strep (MIC ≤0.12 mg/L): Penicillin G 12–18 million units/day by continuous IV infusion or in divided doses × 4 weeks; OR ceftriaxone 2g IV/IM once daily × 4 weeks (equivalent efficacy, logistically simpler, permits outpatient therapy). A 2-week shortened regimen using ceftriaxone + gentamicin is acceptable for uncomplicated native valve IE in younger patients without renal impairment.
• Relatively penicillin-resistant strep (MIC 0.12–0.5 mg/L): Penicillin G or ceftriaxone × 4 weeks + gentamicin for first 2 weeks.
• S. gallolyticus IE: Treat as viridans strep + perform colonoscopy to exclude colorectal cancer (even if asymptomatic).

Enterococcal IE

Enterococci are intrinsically resistant to cephalosporins, oxacillin, and low-level aminoglycosides, and tolerant to the bactericidal effect of penicillins alone. Two combination strategies achieve synergistic killing:

• Ampicillin (2g IV every 4 hours) + ceftriaxone (2g IV every 12 hours) × 6 weeks: Validated in the ACEI trial; effective even against high-level aminoglycoside-resistant (HLAR) strains; nephrotoxicity-sparing. Preferred for E. faecalis IE, especially in patients with renal impairment.
• Ampicillin + gentamicin × 4–6 weeks: Equally effective for ampicillin-susceptible, gentamicin-susceptible E. faecalis; requires careful renal monitoring; avoid if HLAR or creatinine clearance <30 mL/min.
• Vancomycin-resistant Enterococcus (VRE) IE: very limited options — linezolid or daptomycin, both with weak evidence; surgical consultation essential for most VRE IE cases.

HACEK IE

Ceftriaxone 2g IV/IM once daily × 4 weeks (native valve) or 6 weeks (prosthetic valve). Ampicillin + gentamicin is an alternative for beta-lactamase-negative strains.

Culture-Negative and Unusual Organisms

• Coxiella burnetii: Doxycycline 100mg twice daily + hydroxychloroquine 200mg three times daily (oral) × 18 months minimum. Phase I IgG titer >1:800 is both diagnostic and used to monitor response; treatment can be stopped once titer falls below 1:200.
• Bartonella: Ceftriaxone 2g/day + doxycycline 100mg twice daily × 6 weeks (native valve). Add gentamicin for first 3 weeks in prosthetic valve cases.
• Empiric therapy for acutely ill culture-negative IE: Vancomycin + gentamicin + ceftriaxone pending culture results. Adjust when organism and susceptibilities become available.

Outpatient Parenteral Antibiotic Therapy (OPAT)

Carefully selected stable patients with IE caused by penicillin-susceptible streptococci, HACEK, or other susceptible organisms may complete a portion of IV therapy as OPAT after 2 weeks of in-hospital monitoring. Criteria for OPAT candidacy include: clinical stability, no evidence of heart failure or embolic events, no perivalvular extension on imaging, reliable venous access (PICC), caregiver availability, and close outpatient follow-up. IVDU patients require individualized assessment — ongoing drug use creates high relapse risk and limits OPAT candidacy.

Back to Table of Contents

9. Surgical Indications

Approximately 40–50% of IE patients require cardiac surgery during their index hospitalization. Surgery aims to remove infected material, debride perivalvular tissue, and repair or replace the damaged valve. The timing of surgery — urgent, early, or elective — reflects the urgency of the underlying indication and must be balanced against surgical risk, neurological stability, and the likelihood of persistent infection despite antibiotics.

Urgent Surgery (within 24–72 hours, emergency)

• Refractory heart failure from acute severe valvular regurgitation: The most common indication. Acute severe MR or AR causing cardiogenic shock or refractory pulmonary edema requires immediate surgery, as medical management cannot maintain hemodynamic stability. The accepted surgical mortality for emergency IE surgery is 10–20%, but without surgery, mortality approaches 100%.
• Uncontrolled infection: Perivalvular abscess with fistula, pseudoaneurysm formation, or extension to the conduction system unresponsive to antibiotic therapy. Also: fungal IE, IE caused by highly resistant organisms with no effective antimicrobial option, or prosthetic valve IE with persistent bacteremia despite optimized antibiotics.
• Rapidly progressive valvular destruction: Evidence of valvular destruction (perforation, chordal rupture, valve dehiscence) causing hemodynamic compromise before full deterioration into cardiogenic shock.

Early Surgery (within 1 week)

• Embolic prevention: In patients with large (>10mm), highly mobile vegetations who have already suffered one embolic event, surgery in the first week prevents recurrent embolism. The randomized EASE trial (Oh et al., 2013) demonstrated that early surgery within 48 hours significantly reduced embolic events in patients with large vegetations.
• Very large vegetations (>15mm) on the mitral valve even without prior embolism, given the very high embolic risk, are considered by most guidelines as an early surgery indication (especially in patients with otherwise low surgical risk).

Elective Surgery

• Prosthetic valve dysfunction causing hemodynamic instability not meeting the urgent criteria.
• Fungal IE (even if the infection appears controlled with antifungal therapy, surgical debridement and valve replacement substantially improves outcomes).
• Recurrent IE despite adequate treatment courses of antibiotics.

Surgery After Stroke

The coexistence of stroke and the need for cardiac surgery represents one of the most challenging management dilemmas in IE. Cardiac surgery requires anticoagulation and cardiopulmonary bypass, which risk extending hemorrhagic transformation of an ischemic stroke or converting it to hemorrhagic. Current evidence and expert consensus support the following approach:

• Ischemic stroke without hemorrhagic transformation: Surgery can generally proceed safely within 1–3 weeks. The most important predictor of surgical neurological outcome is the degree of neurological recovery and clinical stability — not a fixed time cutoff. Neurological and neurosurgical input is essential.
• Hemorrhagic transformation or intracranial hemorrhage: Delay surgery at least 4 weeks to allow hematoma resolution and hemorrhagic transformation to stabilize.
• Silent cerebral microemboli (on MRI): Do not delay indicated urgent cardiac surgery — silent emboli do not carry the same risk of hemorrhagic conversion as clinical stroke.

Prosthetic Valve Endocarditis — Surgery Threshold

The threshold for surgery is lower in PVE than in native valve IE. Nearly all cases of early PVE with perivalvular extension, hemodynamic instability, or persistent bacteremia will require surgical re-do valve replacement. Late PVE with susceptible organisms and no perivalvular extension may be treated with antibiotics alone in selected cases, with close follow-up echocardiography.

Back to Table of Contents

10. Prevention and Antibiotic Prophylaxis

Antibiotic prophylaxis before dental procedures was once recommended for a broad range of cardiac conditions. The AHA 2007 revised guidelines (updated 2020) dramatically narrowed these indications after systematic review found no compelling evidence that prophylaxis prevents IE in most patients, and recognized that the absolute risk of IE from individual dental procedures is very low even in high-risk patients, while the cumulative risk of antibiotic-related adverse effects (including Clostridium difficile colitis and anaphylaxis) in a broadly prophylaxed population may exceed the benefit. The core principle is now: reserve prophylaxis for patients in whom IE would produce devastating or life-threatening consequences.

Cardiac Conditions Where Prophylaxis IS Recommended

• Prosthetic cardiac valves, including transcatheter-implanted valves (TAVR)
• Prosthetic material used for cardiac valve repair (annuloplasty rings, artificial chordae)
• Prior infective endocarditis (any episode)
• Congenital heart disease (CHD) — specifically:
  • Cyanotic CHD, unrepaired or with residual defects/shunts
  • Completely repaired CHD with prosthetic material during the first 6 months after the procedure (endothelialization is incomplete)
  • Repaired CHD with residual defects at or adjacent to the prosthetic patch or device
• Cardiac transplantation recipients who develop cardiac valvulopathy

Notably excluded: MVP without regurgitation, bicuspid aortic valve without significant dysfunction, and rheumatic heart disease (unless meeting one of the above criteria). These conditions, while increasing IE risk, do not meet the high-risk threshold where prophylaxis benefit is believed to outweigh risk.

Dental Procedures Where Prophylaxis IS Recommended (in High-Risk Cardiac Conditions)

• Any procedure involving manipulation of gingival tissue or the periapical region of teeth
• Any procedure that perforates the oral mucosa

Prophylaxis is NOT required for: routine anesthetic injections through non-infected tissue, dental X-rays, placement or adjustment of removable prosthodontic or orthodontic appliances, bleeding from trauma to the lips or oral mucosa, or shedding of deciduous teeth.

Prophylaxis Regimens

• Standard: Amoxicillin 2g PO, 30–60 minutes before the procedure.
• Unable to take oral medication: Ampicillin 2g IM/IV OR cefazolin/ceftriaxone 1g IM/IV.
• Penicillin allergy (non-anaphylactic): Cephalexin 2g PO OR cefadroxil 2g PO (do not use if anaphylaxis/urticaria/angioedema to PCN — cross-reactivity risk).
• Penicillin allergy (anaphylaxis history) or unable to use cephalosporins: Azithromycin 500mg PO OR clarithromycin 500mg PO OR clindamycin 600mg PO. (Note: clindamycin was removed from the first-line allergy alternative list in the 2021 AHA update due to C. difficile colitis risk, but remains an option.)

Non-Dental Procedures

IE prophylaxis is not recommended for gastrointestinal or genitourinary procedures (colonoscopy, cystoscopy) solely to prevent IE, even in high-risk cardiac patients. If a patient is already receiving antibiotic therapy for a GI or GU infection at the time of a procedure, it is reasonable to select an agent with activity against enterococci.

Non-Pharmacological Prevention

These measures reduce baseline IE risk far more than prophylaxis:

• Meticulous dental hygiene: Daily tooth brushing, flossing, and regular professional cleanings reduce the frequency and magnitude of oral flora bacteremia from daily activities (chewing, brushing) — which account for more cumulative bacteremic episodes than dental procedures. Epidemiological models suggest that maintaining oral hygiene prevents more IE cases than all dental procedure prophylaxis combined.
• Prompt treatment of infections: Early antibiotic treatment of skin infections, dental abscesses, UTIs, and pneumonia reduces bacteremia duration.
• Optimal intravascular catheter care: Strict aseptic technique at insertion, daily catheter site assessment, prompt removal of unnecessary lines — the most impactful interventions in healthcare-associated IE prevention.
• Substance use disorder treatment: IVDU-associated IE will recur unless the underlying addiction is addressed. Medication-assisted treatment (methadone, buprenorphine) and harm reduction strategies (clean needle exchange, supervised injection sites) are evidence-based interventions that reduce IE recurrence rates.
• Endocarditis alert card: All high-risk patients should carry an alert card identifying their cardiac condition to prompt consideration of IE prophylaxis by any future treating dental or medical team.

Back to Table of Contents

11. Prognosis

Infective endocarditis remains a disease with substantial short- and long-term mortality despite advances in antibiotics, echocardiography, and surgical technique. Overall in-hospital mortality is 15–20%, but varies enormously by organism, valve type, complications, and patient characteristics.

Organism-Specific Outcomes

• Staphylococcus aureus: In-hospital mortality 25–45%. The most dangerous organism — fulminant course, frequent valve destruction, high embolism rate, perivalvular extension, and metastatic infection. MRSA IE carries slightly higher mortality than MSSA IE, partly because vancomycin is a less potent anti-staphylococcal agent than nafcillin.
• Viridans group streptococci: In-hospital mortality 4–6% with appropriate therapy. Subacute course, preserved valve function in many cases, high antibiotic sensitivity. The most favorable prognosis among common IE pathogens.
• Enterococcus: In-hospital mortality 15–25%. Intrinsic antibiotic resistance and older, comorbid patient population contribute to worse outcomes.
• Fungal IE: In-hospital mortality 50–60% even with surgery + antifungal therapy. Medical therapy alone nearly uniformly fatal.
• HACEK: In-hospital mortality <5% with ceftriaxone therapy; high embolic risk but generally curative with antibiotics alone.

Valve-Type and Structural Factors

• Prosthetic valve IE: In-hospital mortality 20–30%, higher than native valve IE for comparable organisms. Early PVE carries higher mortality than late PVE.
• Right-sided (tricuspid) IE: In-hospital mortality 5–10%, significantly better than left-sided IE. The pulmonary circulation filters septic emboli before they reach systemic circulation, and tricuspid valve function is more surgically expendable (tricuspid valvectomy without replacement is tolerated by many IVDU patients).
• Perivalvular abscess: Doubles operative mortality compared to IE without abscess.

Predictors of Poor Outcome

The following variables are independently associated with increased in-hospital or 1-year mortality:

• Age >70 years (reduced physiologic reserve, more comorbidities)
• Heart failure at presentation
• Staphylococcus aureus as causative organism
• Prosthetic valve infection
• Perivalvular extension / abscess
• Large vegetation on echocardiography (>10mm)
• Renal failure (creatinine >2.0 mg/dL)
• Stroke or other cerebrovascular complication at presentation
• Delay to surgery when surgical indication is present

Long-Term Outcomes

Among 1-year survivors, the majority have residual valvular dysfunction requiring ongoing follow-up. Key long-term considerations:

• Recurrence: The risk of recurrent IE is 2–6% per year — substantially higher than the general population background rate. Prior IE is the strongest predictor of subsequent IE. Dental hygiene, prophylaxis awareness, and — critically — sustained abstinence from IVDU are the most important modifiable factors.
• Surgical follow-up: Patients who underwent valve repair or replacement require regular echocardiographic surveillance, anticoagulation management (mechanical valves), and bioprosthetic valve degeneration monitoring.
• IVDU recidivism: Patients who return to injection drug use after IVDU-associated IE have recurrence rates of 30–40% within 2 years. Substance use disorder treatment is a medical imperative alongside cardiac management — multidisciplinary teams including addiction medicine specialists are now recommended by AHA and IDSA guidelines.
• Endocarditis alert and dental care: All patients with prior IE should be counseled to inform all future dental and medical providers of their history, maintain rigorous dental hygiene, and carry an endocarditis alert card.

Back to Table of Contents

12. Research Papers

1. Habib G et al. 2015 ESC Guidelines for the management of infective endocarditis. Eur Heart J. 2015;36(44):3075–3128.
2. Baddour LM et al. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications. Circulation. 2015;132(15):1435–1486.
3. Delgado V et al. 2023 ESC Guidelines for the management of endocarditis. Eur Heart J. 2023;44(39):3948–4042.
4. Cahill TJ et al. Infective endocarditis. Lancet. 2016;387(10021):882–893.
5. Pettersson GB et al. Successful management of infective endocarditis. J Thorac Cardiovasc Surg. 2020;160(1):198–207.
6. Li JS et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis. 2000;30(4):633–638.
7. Thuny F et al. Management of infective endocarditis: challenges and perspectives. Lancet. 2012;379(9819):965–975.
8. Naber CK et al. Role of surgery in infective endocarditis. Curr Infect Dis Rep. 2012;14(3):318–325.
9. Ferreira JP et al. Tricuspid valve infective endocarditis. J Am Coll Cardiol. 2017;70(22):2725–2737.
10. Wilson WR et al. Prevention of infective endocarditis. Circulation. 2007;116(15):1736–1754.
11. Mestres CA et al. Endocarditis team and a multidisciplinary approach. Ann Cardiothorac Surg. 2019;8(6):603–606.
12. Murdoch DR et al. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century. Arch Intern Med. 2009;169(5):463–473.

Back to Table of Contents

Connections

• Endocarditis
• Valvular Heart Disease
• Heart Failure
• Arrhythmia
• Myocarditis
• Pericarditis
• Heart Block
• Atrial Fibrillation
• Stroke
• Aortic Stenosis
• Cardiovascular Disease
• All Conditions

Back to Table of Contents

Featured Videos